Genentech’s Giredestrant Combination Shows Strong PFS Improvement in…

Event summary

Genentech’s Phase III evERA trial data, published in The New England Journal of Medicine, showed giredestrant plus everolimus significantly improved progression-free survival (PFS) in ER-positive advanced breast cancer patients.
In the ESR1-mutated population, median PFS was 10.0 months with giredestrant vs. 5.5 months with standard therapy (HR=0.38, p<0.001).
The FDA accepted Genentech’s NDA for giredestrant in combination with everolimus, with a decision expected by December 18, 2026.
Additional evERA analyses presented at the 2026 ASCO Annual Meeting showed prolonged PFS2 and chemotherapy-free survival with the giredestrant combination.

The big picture

Genentech’s positive Phase III evERA data for giredestrant reinforces its potential to redefine care in both metastatic and early-stage ER-positive breast cancer. The results come at a time when resistance to endocrine therapies remains a critical challenge, with up to 40% of patients developing ESR1 mutations post-CDK inhibitor treatment. The FDA’s decision on the NDA will be a key milestone in determining the drug’s market entry and competitive positioning.

What we're watching

Regulatory Approval: Whether the FDA will approve giredestrant by the December 18, 2026 deadline, potentially expanding treatment options for ER-positive advanced breast cancer.
Clinical Efficacy: The pace at which overall survival data matures and whether it confirms the positive trend observed in the evERA trial.
Market Positioning: How Genentech positions giredestrant against existing therapies in the post-CDK inhibitor setting, given the unmet need for effective treatments.